Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2020-09-28 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Sub.: Outcome & Submission of Voting Results of the 32nd Annual General Meeting (AGM) held on Monday, 28th September, 2020. Pursuant to Regulation 44 (3) of the SEBI (Listing Obligations ....
Regulatory Filings
2020-09-28 English
Financial Result Updates
Regulatory Filings
2020-09-11 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from the Board of Directors regarding the outcome of a board meeting held on 11th September 2020. It includes approval of standalone and consolidated unaudited financial results for the first quarter ended 30th June 2020, allotment of equity shares due to exercise of employee stock options, and details about the ESOP scheme. It also mentions the submission of a Limited Review Report. The document is not the full quarterly report itself but an official announcement of the board meeting outcomes including financial results and share allotment details. It contains substantive financial data and disclosures related to share capital changes and employee stock options. This fits best under Capital/Financing Update (CAP) because it involves share allotment and ESOP issuance, along with financial results approval. It is not a full Interim/Quarterly Report (IR) because it does not contain full financial statements or detailed analysis, but rather the outcome of the board meeting and related disclosures. Therefore, the classification is CAP with high confidence.
2020-09-11 English
i) Standalone & Consolidated Un-audited Financial Results (UFR) of the Company for the first quarter ended 30th June, 2020. ii) Allotment of 20,000 Equity Shares of the Company under ....
Regulatory Filings
2020-09-11 English
This is with reference to the above mentioned subject, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. 11th September, 2020 has ....
Regulatory Filings
2020-09-11 English
Book Closure
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for omitted pictures and no substantive text or financial data. The true document length is only 165 characters, which is extremely short and contains no report content. There is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category for miscellaneous filings without substantive information.
2020-09-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.